Global T-cell Acute Lymphoblastic Leukemia Market: Industry Analysis and forecast (2019 to 2026): By Treatment, End Users, and Region

Global T-cell Acute Lymphoblastic Leukemia Market: Industry Analysis and forecast (2019 to 2026): By Treatment, End Users, and Region

Market Scenario

Global T-cell Acute Lymphoblastic Leukemia Market was valued USD XX Bn in 2018 and is expected to reach US$ 3.52 Bn by 2026, at CAGR of XX% during forecast period of 2019 to 2026. The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. Global T-cell Acute Lymphoblastic Leukemia Market Drivers and Restrains: T-cell acute lymphoblastic leukemia is a category, with features like to lymphoma and it affects white blood cells called T lymphocytes. T-ALL is most common between children aged over five years. The T-cell acute lymphoblastic leukemia market is likely to a significant growth rate during the forecast period owing to increase in cancer awareness programs and strong product pipeline. Treatment of this disease includes chemotherapy, radiation therapy, bone marrow transplant, targeted therapy, and immunotherapy. Rise in prevalence of T-ALL and rapid technological advancements boost the global T-cell acute lymphoblastic leukemia market. T-cell acute lymphoblastic leukemia estimated for 15% to 20% of all acute lymphoblastic leukemia by study of the American Society of Clinical Oncology (ASCO). In 2018, according to a recent study approximately 5,970 cases of acute lymphoblastic leukemia (ALL) were reported in the U.S. About 4 in 10 cases were in adults. There is a rise in the number of cases in the Asia-Pacific region mainly due to the adoption of western lifestyles containing dietary changes and sedentary lifestyles. Furthermore, increase in health care investment and rise in number of clinical trials are expected to impel the global T-cell acute lymphoblastic leukemia market. The high cost of treatment with strict rule on drug safety that may hinder the market growth at global level. Manufacturers in the T-cell acute lymphoblastic leukemia are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers. Global T-cell Acute Lymphoblastic Leukemia Market Segmentation Analysis: Based on the treatment, the global market has segmented into chemotherapy, radiation therapy, bone marrow transplant, targeted therapy, and immunotherapy. The chemotherapy treatment segment accounted for majority market share of the T-cell acute lymphoblastic leukemia market in terms of revenue in 2018. The segment is projected to grow at a significant CAGR during the forecast period owing to its high prescription rate, wide range of products, and easy availability. Based on the end-user, the global T-cell acute lymphoblastic leukemia market has been classified into hospitals, clinics, and others. The hospitals segment prominent the global market in 2018, and the trend is expected to continue during the forecast period. This is attributed to the increase in health care infrastructure, favorable reimbursement policies, and surge in awareness among individuals about T-ALL. Moreover, hospitals provide advanced medical treatment to treat T-cell acute lymphoblastic leukemia patients. Global T-cell Acute Lymphoblastic Leukemia Market Regional Analysis: Geographically, the global T-cell acute lymphoblastic leukemia market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest market in 2018 and is projected to hold the market share during the forecast period. Increase in incidence of T-cell acute lymphoblastic leukemia, new product approvals, strong product pipeline, and rise in health care expenditure will fuel the market. The T-cell acute lymphoblastic leukemia market in Asia Pacific is anticipated to expand at a rapid pace during the forecast period. Japan dominated the T-cell acute lymphoblastic leukemia market in the region. The market in India is expected to grow at a high CAGR of XX% during the forecast period. The objective of the report is to present comprehensive analysis of global T-cell acute lymphoblastic leukemia market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding global T-cell acute lymphoblastic leukemia market dynamics, structure by analyzing the market segments, and project the global T-cell acute lymphoblastic leukemia market size. Clear representation of competitive analysis of key players by treatment, price, financial position, product portfolio, growth strategies, and regional presence in the global T-cell acute lymphoblastic leukemia market make the report investor’s guide.

Scope of the Global T-cell Acute Lymphoblastic Leukemia Market:

Global T-cell Acute Lymphoblastic Leukemia Market, by Treatment:

• Chemotherapy • Radiation Therapy • Bone Marrow Transplant • Targeted Therapy • Immunotherapy Global T-cell Acute Lymphoblastic Leukemia Market, by End Users: • Hospitals • Clinics • Others

Global T-cell Acute Lymphoblastic Leukemia Market, by Region:

• Asia Pacific • North America • Europe • Latin America • Middle East Africa

Global T-cell Acute Lymphoblastic Leukemia Market, Major Players:

• Novartis AG • Amgen, Inc. • Bristol-Myers Squibb Company • CELGENE CORPORATION • Erytech Pharma Inc. • F. Hoffmann-La Roche Ltd. • Pfizer, Inc. • Sanofi • Spectrum Pharmaceuticals, Inc. • Bristol-Myers Squibb Company • SymBio Pharmaceuticals Limited • Eisai Co Ltd • GlaxoSmithKline • Takeda Pharmaceutical Company Limited • Rare Disease Therapeutics Global Atomic Force Microscopes Market 

Table of Contents

Global T-cell Acute Lymphoblastic Leukemia Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global T-cell Acute Lymphoblastic Leukemia Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 4.8. Patent Registration 5. Supply Side and Demand Side Indicators 6. Global T-cell Acute Lymphoblastic Leukemia Market Analysis and Forecast 6.1. Global T-cell Acute Lymphoblastic Leukemia Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global T-cell Acute Lymphoblastic Leukemia Market Analysis and Forecast, by Treatment 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Treatment 7.4. Global T-cell Acute Lymphoblastic Leukemia Market Size (US$ Bn) Forecast, by Treatment 7.5. Global T-cell Acute Lymphoblastic Leukemia Market Analysis, by Treatment 7.6. Global T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Treatment 8. Global T-cell Acute Lymphoblastic Leukemia Market Analysis and Forecast, by End Users 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End Users 8.4. Global T-cell Acute Lymphoblastic Leukemia Market Size (US$ Bn) Forecast, by End Users 8.5. Global T-cell Acute Lymphoblastic Leukemia Market Analysis, by End Users 8.6. Global T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End Users 9. Global T-cell Acute Lymphoblastic Leukemia Market Analysis, by Region 9.1. Global T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Region 9.2. Global T-cell Acute Lymphoblastic Leukemia Market Size (US$ Bn) Forecast, by Region 9.3. Global T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Region 10. North America T-cell Acute Lymphoblastic Leukemia Market Analysis 10.1. Key Findings 10.2. North America T-cell Acute Lymphoblastic Leukemia Market Overview 10.3. North America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Treatment 10.4. North America T-cell Acute Lymphoblastic Leukemia Market Forecast, by Treatment 10.4.1. Chemotherapy 10.4.2. Radiation Therapy 10.4.3. Bone Marrow Transplant 10.4.4. Targeted Therapy 10.4.5. Immunotherapy 10.5. North America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End Users 10.6. North America T-cell Acute Lymphoblastic Leukemia Market Forecast, by End Users 10.6.1. Hospitals 10.6.2. Clinics 10.6.3. Others 10.7. North America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country 10.8. North America T-cell Acute Lymphoblastic Leukemia Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America T-cell Acute Lymphoblastic Leukemia Market Analysis, by Country 10.10. U.S. T-cell Acute Lymphoblastic Leukemia Market Forecast, by Treatment 10.10.1. Chemotherapy 10.10.2. Radiation Therapy 10.10.3. Bone Marrow Transplant 10.10.4. Targeted Therapy 10.10.5. Immunotherapy 10.11. U.S. T-cell Acute Lymphoblastic Leukemia Market Forecast, by End Users 10.11.1. Hospitals 10.11.2. Clinics 10.11.3. Others 10.12. Canada T-cell Acute Lymphoblastic Leukemia Market Forecast, by Treatment 10.12.1. Chemotherapy 10.12.2. Radiation Therapy 10.12.3. Bone Marrow Transplant 10.12.4. Targeted Therapy 10.12.5. Immunotherapy 10.13. Canada T-cell Acute Lymphoblastic Leukemia Market Forecast, by End Users 10.13.1. Hospitals 10.13.2. Clinics 10.13.3. Others 10.14. North America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis 10.14.1. By Treatment 10.14.2. By End Users 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Development 11. Europe T-cell Acute Lymphoblastic Leukemia Market Analysis 11.1. Key Findings 11.2. Europe T-cell Acute Lymphoblastic Leukemia Market Overview 11.3. Europe T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Treatment 11.4. Europe T-cell Acute Lymphoblastic Leukemia Market Forecast, by Treatment 11.4.1. Chemotherapy 11.4.2. Radiation Therapy 11.4.3. Bone Marrow Transplant 11.4.4. Targeted Therapy 11.4.5. Immunotherapy 11.5. Europe T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End Users 11.6. Europe T-cell Acute Lymphoblastic Leukemia Market Forecast, by End Users 11.6.1. Hospitals 11.6.2. Clinics 11.6.3. Others 11.7. Europe T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country 11.8. Europe T-cell Acute Lymphoblastic Leukemia Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe T-cell Acute Lymphoblastic Leukemia Market Analysis, by Country 11.10. Germany T-cell Acute Lymphoblastic Leukemia Market Forecast, by Treatment 11.10.1. Chemotherapy 11.10.2. Radiation Therapy 11.10.3. Bone Marrow Transplant 11.10.4. Targeted Therapy 11.10.5. Immunotherapy 11.11. Germany T-cell Acute Lymphoblastic Leukemia Market Forecast, by End Users 11.11.1. Hospitals 11.11.2. Clinics 11.11.3. Others 11.12. U.K. T-cell Acute Lymphoblastic Leukemia Market Forecast, by Treatment 11.12.1. Chemotherapy 11.12.2. Radiation Therapy 11.12.3. Bone Marrow Transplant 11.12.4. Targeted Therapy 11.12.5. Immunotherapy 11.13. U.K. T-cell Acute Lymphoblastic Leukemia Market Forecast, by End Users 11.13.1. Hospitals 11.13.2. Clinics 11.13.3. Others 11.14. France T-cell Acute Lymphoblastic Leukemia Market Forecast, by Treatment 11.14.1. Chemotherapy 11.14.2. Radiation Therapy 11.14.3. Bone Marrow Transplant 11.14.4. Targeted Therapy 11.14.5. Immunotherapy 11.15. France T-cell Acute Lymphoblastic Leukemia Market Forecast, by End Users 11.15.1. Hospitals 11.15.2. Clinics 11.15.3. Others 11.16. Italy T-cell Acute Lymphoblastic Leukemia Market Forecast, by Treatment 11.16.1. Chemotherapy 11.16.2. Radiation Therapy 11.16.3. Bone Marrow Transplant 11.16.4. Targeted Therapy 11.16.5. Immunotherapy 11.17. Italy T-cell Acute Lymphoblastic Leukemia Market Forecast, by End Users 11.17.1. Hospitals 11.17.2. Clinics 11.17.3. Others 11.18. Spain T-cell Acute Lymphoblastic Leukemia Market Forecast, by Treatment 11.18.1. Chemotherapy 11.18.2. Radiation Therapy 11.18.3. Bone Marrow Transplant 11.18.4. Targeted Therapy 11.18.5. Immunotherapy 11.19. Spain T-cell Acute Lymphoblastic Leukemia Market Forecast, by End Users 11.19.1. Hospitals 11.19.2. Clinics 11.19.3. Others 11.20. Rest of Europe T-cell Acute Lymphoblastic Leukemia Market Forecast, by Treatment 11.20.1. Chemotherapy 11.20.2. Radiation Therapy 11.20.3. Bone Marrow Transplant 11.20.4. Targeted Therapy 11.20.5. Immunotherapy 11.21. Rest of Europe T-cell Acute Lymphoblastic Leukemia Market Forecast, by End Users 11.21.1. Hospitals 11.21.2. Clinics 11.21.3. Others 11.22. Europe T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis 11.22.1. By Treatment 11.22.2. By End Users 11.23. PEST Analysis 11.24. Key Trend 11.25. Key Development 12. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Analysis 12.1. Key Findings 12.2. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Overview 12.3. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Treatment 12.4. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Forecast, by Treatment 12.4.1. Chemotherapy 12.4.2. Radiation Therapy 12.4.3. Bone Marrow Transplant 12.4.4. Targeted Therapy 12.4.5. Immunotherapy 12.5. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End Users 12.6. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Forecast, by End Users 12.6.1. Hospitals 12.6.2. Clinics 12.6.3. Others 12.7. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country 12.8. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Analysis, by Country 12.10. China T-cell Acute Lymphoblastic Leukemia Market Forecast, by Treatment 12.10.1. Chemotherapy 12.10.2. Radiation Therapy 12.10.3. Bone Marrow Transplant 12.10.4. Targeted Therapy 12.10.5. Immunotherapy 12.11. China T-cell Acute Lymphoblastic Leukemia Market Forecast, by End Users 12.11.1. Hospitals 12.11.2. Clinics 12.11.3. Others 12.12. India T-cell Acute Lymphoblastic Leukemia Market Forecast, by Treatment 12.12.1. Chemotherapy 12.12.2. Radiation Therapy 12.12.3. Bone Marrow Transplant 12.12.4. Targeted Therapy 12.12.5. Immunotherapy 12.13. India T-cell Acute Lymphoblastic Leukemia Market Forecast, by End Users 12.13.1. Hospitals 12.13.2. Clinics 12.13.3. Others 12.14. Japan T-cell Acute Lymphoblastic Leukemia Market Forecast, by Treatment 12.14.1. Chemotherapy 12.14.2. Radiation Therapy 12.14.3. Bone Marrow Transplant 12.14.4. Targeted Therapy 12.14.5. Immunotherapy 12.15. Japan T-cell Acute Lymphoblastic Leukemia Market Forecast, by End Users 12.15.1. Hospitals 12.15.2. Clinics 12.15.3. Others 12.16. ASEAN T-cell Acute Lymphoblastic Leukemia Market Forecast, by Treatment 12.16.1. Chemotherapy 12.16.2. Radiation Therapy 12.16.3. Bone Marrow Transplant 12.16.4. Targeted Therapy 12.16.5. Immunotherapy 12.17. ASEAN T-cell Acute Lymphoblastic Leukemia Market Forecast, by End Users 12.17.1. Hospitals 12.17.2. Clinics 12.17.3. Others 12.18. Rest of Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Forecast, by Treatment 12.18.1. Chemotherapy 12.18.2. Radiation Therapy 12.18.3. Bone Marrow Transplant 12.18.4. Targeted Therapy 12.18.5. Immunotherapy 12.19. Rest of Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Forecast, by End Users 12.19.1. Hospitals 12.19.2. Clinics 12.19.3. Others 12.20. Asia Pacific T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis 12.20.1. By Treatment 12.20.2. By End Users 12.21. PEST Analysis 12.22. Key Trend 12.23. Key Development 13. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Analysis 13.1. Key Findings 13.2. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Overview 13.3. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Treatment 13.4. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Forecast, by Treatment 13.4.1. Chemotherapy 13.4.2. Radiation Therapy 13.4.3. Bone Marrow Transplant 13.4.4. Targeted Therapy 13.4.5. Immunotherapy 13.5. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End Users 13.6. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Forecast, by End Users 13.6.1. Hospitals 13.6.2. Clinics 13.6.3. Others 13.7. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country 13.8. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Analysis, by Country 13.10. GCC T-cell Acute Lymphoblastic Leukemia Market Forecast, by Treatment 13.10.1. Chemotherapy 13.10.2. Radiation Therapy 13.10.3. Bone Marrow Transplant 13.10.4. Targeted Therapy 13.10.5. Immunotherapy 13.11. GCC T-cell Acute Lymphoblastic Leukemia Market Forecast, by End Users 13.11.1. Hospitals 13.11.2. Clinics 13.11.3. Others 13.12. South Africa T-cell Acute Lymphoblastic Leukemia Market Forecast, by Treatment 13.12.1. Chemotherapy 13.12.2. Radiation Therapy 13.12.3. Bone Marrow Transplant 13.12.4. Targeted Therapy 13.12.5. Immunotherapy 13.13. South Africa T-cell Acute Lymphoblastic Leukemia Market Forecast, by End Users 13.13.1. Hospitals 13.13.2. Clinics 13.13.3. Others 13.14. Rest of Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Forecast, by Treatment 13.14.1. Chemotherapy 13.14.2. Radiation Therapy 13.14.3. Bone Marrow Transplant 13.14.4. Targeted Therapy 13.14.5. Immunotherapy 13.15. Rest of Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Forecast, by End Users 13.15.1. Hospitals 13.15.2. Clinics 13.15.3. Others 13.16. Middle East & Africa T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis 13.16.1. By Treatment 13.16.2. By End Users 13.17. PEST Analysis 13.18. Key Trend 13.19. Key Development 14. South America T-cell Acute Lymphoblastic Leukemia Market Analysis 14.1. Key Findings 14.2. South America T-cell Acute Lymphoblastic Leukemia Market Overview 14.3. South America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Treatment 14.4. South America T-cell Acute Lymphoblastic Leukemia Market Forecast, by Treatment 14.4.1. Chemotherapy 14.4.2. Radiation Therapy 14.4.3. Bone Marrow Transplant 14.4.4. Targeted Therapy 14.4.5. Immunotherapy 14.5. Others South America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by End Users 14.6. South America T-cell Acute Lymphoblastic Leukemia Market Forecast, by End Users 14.6.1. Hospitals 14.6.2. Clinics 14.6.3. Others 14.7. South America T-cell Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country 14.8. South America T-cell Acute Lymphoblastic Leukemia Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. Brazil T-cell Acute Lymphoblastic Leukemia Market Forecast, by Treatment 14.9.1. Chemotherapy 14.9.2. Radiation Therapy 14.9.3. Bone Marrow Transplant 14.9.4. Targeted Therapy 14.9.5. Immunotherapy 14.10. Brazil T-cell Acute Lymphoblastic Leukemia Market Forecast, by End Users 14.10.1. Hospitals 14.10.2. Clinics 14.10.3. Others 14.11. Mexico T-cell Acute Lymphoblastic Leukemia Market Forecast, by Treatment 14.11.1. Chemotherapy 14.11.2. Radiation Therapy 14.11.3. Bone Marrow Transplant 14.11.4. Targeted Therapy 14.11.5. Immunotherapy 14.12. Mexico T-cell Acute Lymphoblastic Leukemia Market Forecast, by End Users 14.12.1. Hospitals 14.12.2. Clinics 14.12.3. Others 14.13. Rest of South America T-cell Acute Lymphoblastic Leukemia Market Forecast, by Treatment 14.13.1. Chemotherapy 14.13.2. Radiation Therapy 14.13.3. Bone Marrow Transplant 14.13.4. Targeted Therapy 14.13.5. Immunotherapy 14.14. Rest of South America T-cell Acute Lymphoblastic Leukemia Market Forecast, by End Users 14.14.1. Hospitals 14.14.2. Clinics 14.14.3. Others 14.15. South America T-cell Acute Lymphoblastic Leukemia Market Attractiveness Analysis 14.15.1. By Treatment 14.15.2. By End Users 14.16. PEST Analysis 14.17. Key Trend 14.18. Key Development 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and Applications 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Novartis AG 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Company Footprint 15.3.2. Amgen, Inc. 15.3.3. Bristol-Myers Squibb Company 15.3.4. CELGENE CORPORATION, Erytech Pharma Inc. 15.3.5. F. Hoffmann-La Roche Ltd. 15.3.6. Pfizer, Inc. 15.3.7. Sanofi 15.3.8. Spectrum Pharmaceuticals, Inc. 15.3.9. Bristol-Myers Squibb Company 15.3.10. SymBio Pharmaceuticals Limited 15.3.11. Eisai Co Ltd 15.3.12. Erytech Pharma 15.3.13. GlaxoSmithKline 15.3.14. Takeda Pharmaceutical Company Limited 15.3.15. Rare Disease Therapeutics 16. Primary Key Insights

About This Report

Report ID36099
Category Healthcare
Published DateNov 2019
No of Pages300
Contact Us
Call Now